MANKIND PHARMA Financial Statement Analysis
|
||
The Revenues of MANKIND PHARMA have increased by 12.44% YoY .
The Earnings Per Share (EPS) of MANKIND PHARMA has increased by 49.22 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
MANKIND PHARMA Last 5 Annual Financial Results
[BOM: 543904|NSE : MANKIND]
Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
---|---|---|---|---|---|
Revenues | ₹8,749 Cr | ₹7,782 Cr | ₹621 Cr | ₹58,719 Cr | ₹4,980 Cr |
Expenses | ₹6,848 Cr | ₹5,791 Cr | ₹457 Cr | ₹44,272 Cr | ₹4,055 Cr |
Operating Profit (Excl OI) | ₹1,902 Cr | ₹1,991 Cr | ₹165 Cr | ₹14,447 Cr | ₹925 Cr |
Other Income | ₹129 Cr | ₹196 Cr | ₹17 Cr | ₹1,038 Cr | ₹53 Cr |
Interest | ₹46 Cr | ₹60 Cr | ₹2.12 Cr | ₹232 Cr | ₹44 Cr |
Depreciation | ₹326 Cr | ₹167 Cr | ₹12 Cr | ₹991 Cr | ₹69 Cr |
Profit Before Tax | ₹1,671 Cr | ₹1,975 Cr | ₹169 Cr | ₹14,377 Cr | ₹875 Cr |
Profit After Tax | ₹1,310 Cr | ₹1,453 Cr | ₹129 Cr | ₹10,561 Cr | ₹610 Cr |
Consolidated Net Profit | ₹1,282 Cr | ₹1,433 Cr | ₹127 Cr | ₹10,304 Cr | ₹579 Cr |
Earnings Per Share (Rs) | ₹47.75 | ₹32.00 | ₹35.78 | ₹31.59 | ₹25.72 |
PAT Margin (%) | 18.06 | 14.38 | 18.00 | 20.00 | 17.31 |
ROE(%) | 23.15 | 19.27 | 26.72 | 31.51 | 33.48 |
ROCE(%) | 28.38 | 23.49 | 33.96 | 39.97 | 43.57 |
Total Debt/Equity(x) | 0.02 | 0.02 | 0.14 | 0.05 | 0.04 |
Key Financials |
||
Market Cap | : | ₹ 98,473.2 Cr |
Revenue (TTM) | : | ₹ 11,641.0 Cr |
Net Profit(TTM) | : | ₹ 2,050.7 Cr |
EPS (TTM) | : | ₹ 49.7 |
P/E (TTM) | : | 48.0 |
Industry Peers & Returns | 1W | 1M | 1Y |
MANKIND PHARMA | -1.4% | -6.9% | 5.9% |
SUN PHARMACEUTICAL INDUSTRIES | 0.5% | -3.4% | 13.4% |
CIPLA | 2.2% | 3.9% | 2.3% |
DR REDDYS LABORATORIES | -1.5% | -7% | -5% |
ZYDUS LIFESCIENCES | -2.3% | -7.4% | 3.7% |
DIVIS LABORATORIES | -2.2% | 0.3% | 58.8% |
TORRENT PHARMACEUTICALS | -0.6% | -3.5% | 16.5% |
LUPIN | -0.6% | -4.3% | 25% |
AUROBINDO PHARMA | 1.7% | -1.9% | 13.2% |
MANKIND PHARMA Revenues
[BOM: 543904|NSE : MANKIND]
Y-o-Y | 12.44 % |
5 Yr CAGR | 15.13 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹8,749 Cr | 12.44 | |
Mar2023 | ₹7,782 Cr | 1,152.18 | |
Mar2022 | ₹621 Cr | -98.94 | |
Mar2021 | ₹58,719 Cr | 1,079.10 | |
Mar2020 | ₹4,980 Cr | - |
MANKIND PHARMA Operating Profit
[BOM: 543904|NSE : MANKIND]
Y-o-Y | -4.45 % |
5 Yr CAGR | 19.75 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹1,902 Cr | -4.45 | |
Mar2023 | ₹1,991 Cr | 1,107.04 | |
Mar2022 | ₹165 Cr | -98.86 | |
Mar2021 | ₹14,447 Cr | 1,461.81 | |
Mar2020 | ₹925 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -15.01 % |
5 Yr CAGR | 4.02 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 21.74% | -15.01 | |
Mar2023 | 25.58% | -3.62 | |
Mar2022 | 26.54% | 7.89 | |
Mar2021 | 24.6% | 32.47 | |
Mar2020 | 18.57% | - |
MANKIND PHARMA Profit After Tax
[BOM: 543904|NSE : MANKIND]
Y-o-Y | -10.58 % |
5 Yr CAGR | 22.01 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹1,282 Cr | -10.58 | |
Mar2023 | ₹1,433 Cr | 1,032.80 | |
Mar2022 | ₹127 Cr | -98.77 | |
Mar2021 | ₹10,304 Cr | 1,681.10 | |
Mar2020 | ₹579 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 25.59 % |
5 Yr CAGR | 1.07 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 18.06 % | 25.59 | |
Mar2023 | 14.38 % | -20.11 | |
Mar2022 | 18 % | -10.00 | |
Mar2021 | 20 % | 15.54 | |
Mar2020 | 17.31 % | - |
MANKIND PHARMA Earnings Per Share (EPS)
[BOM: 543904|NSE : MANKIND]
Y-o-Y | 49.22 % |
5 Yr CAGR | 16.73 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹48 | 49.22 | |
Mar2023 | ₹32 | -10.56 | |
Mar2022 | ₹36 | 13.26 | |
Mar2021 | ₹32 | 22.82 | |
Mar2020 | ₹26 | - |
MANKIND PHARMA Return on Capital Employed (ROCE)
[BOM: 543904|NSE : MANKIND]
Y-o-Y | 20.82 % |
5 Yr CAGR | -10.16 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 28.38% | 20.82 | |
Mar2023 | 23.49% | -30.83 | |
Mar2022 | 33.96% | -15.04 | |
Mar2021 | 39.97% | -8.26 | |
Mar2020 | 43.57% | - |
MANKIND PHARMA Share Price vs Sensex
Current Share Price | : | ₹2,386.7 |
Current MarketCap | : | ₹ 98,473.2 Cr |
Updated EOD on | : | Feb 18,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MANKIND PHARMA | -1.4% |
-6.9% |
5.9% |
SENSEX | -0.4% |
-1.4% |
5.4% |
MANKIND PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE LARGECAP | -0.8% | -3.1% | 3.4% |
S&P BSE 100 LARGECAP TMC | -0.9% | -3.1% | 3.4% |
S&P BSE 200 | -1.1% | -4% | 3.6% |
S&P BSE LARGE MIDCAP | -1.1% | -4.2% | 2.9% |
S&P BSE 250 LARGEMIDCAP | -1.2% | -4.3% | 3.2% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 200 | -1.1% | -4.1% | 3.7% |
NIFTY PHARMA | -1.3% | -5.5% | 12.9% |
NIFTY LARGE MIDCAP 250 | -1.6% | -6.3% | 3.5% |
NIFTY 500 | -1.6% | -5.5% | 2.9% |
NIFTY FREE MIDCAP 100 | -2.2% | -9.7% | 1.9% |
You may also like the below Video Courses
FAQ about MANKIND PHARMA Financials
How the annual revenues of MANKIND PHARMA have changed ?
The Revenues of MANKIND PHARMA have increased by 12.44% YoY .
How the Earnings per Share (EPS) of MANKIND PHARMA have changed?
The Earnings Per Share (EPS) of MANKIND PHARMA has increased by 49.22 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs